Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
4.380
+0.280 (6.83%)
At close: Jun 26, 2026, 4:00 PM EDT
4.380
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:23 PM EDT

Prelude Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
42818370234289593
Market Cap Growth
422.04%160.66%-70.13%-18.95%-51.18%-81.05%
Enterprise Value
339.3297.14-45.5521.7889.41303.16
Last Close Price
4.382.901.274.276.0412.45
PS Ratio
24.1115.0410.01---
PB Ratio
5.622.660.530.991.482.07
P/TBV Ratio
5.723.250.731.091.462.01
EV/Sales Ratio
20.298.00-6.51---
EV/EBITDA Ratio
--0.33---
EV/EBIT Ratio
--0.33---
EV/FCF Ratio
--0.44---
Debt / Equity Ratio
0.250.220.120.0800
Net Debt / Equity Ratio
-1.06-1.25-0.88-0.90-1.02-1.01
Net Debt / EBITDA Ratio
0.770.830.841.621.642.57
Net Debt / FCF Ratio
1.461.521.121.922.303.37
Asset Turnover
-0.080.03000
Quick Ratio
1.951.955.2110.679.3015.17
Current Ratio
2.031.995.3010.799.4215.37
Return on Equity (ROE)
-120.79%-99.45%-69.01%-56.34%-47.97%-44.85%
Return on Assets (ROA)
-64.48%-66.01%-61.66%-53.11%-47.01%-43.03%
Return on Invested Capital (ROIC)
-119.46%-182.77%-325.38%-430.11%-832.62%-1568.33%
Return on Capital Employed (ROCE)
-101.22%-87.80%-68.87%-58.19%-50.98%-45.67%
Buyback Yield / Dilution
-3.59%-1.52%-25.60%-27.41%-2.87%-269.03%
Total Shareholder Return
-3.59%-1.52%-25.60%-27.41%-2.87%-269.03%
SEC Filings: 10-K · 10-Q